An Open Label, Randomised, Parallel Group, Multicentre, Non-inferiority Study to Compare ZOLADEX 10.8 mg With ZOLADEX 3.6 mg in Chinese Pre-menopausal Patients With Estrogen Receptor-Positive and HER2 Negative Early Breast Cancer
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2018
At a glance
- Drugs Goserelin (Primary)
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms LARES
- Sponsors AstraZeneca
- 30 Nov 2018 Planned End Date changed from 10 Jun 2020 to 31 Dec 2020.
- 30 Nov 2018 Planned primary completion date changed from 10 Jun 2020 to 31 Dec 2020.
- 30 Nov 2018 Planned initiation date changed from 5 Nov 2018 to 30 Apr 2019.